Published in final edited form as:

Tetrahedron Lett. 2015 January 8; 56(2): 458–460. doi:10.1016/j.tetlet.2014.11.126.

Facile syntheses of functionalized toll-like receptor 7 agonists

Babatope Akinbobuyi^a, Matthew R. Byrd^a, Charles A. Chang^b, Mysa Nguyen^a, Zacharie J. Seifert^a, Anne-Laure Flamar^c, Gerard Zurawski^{b,c}, Katherine C. Upchurch^b, SangKon Oh^{b,c}, Stephen H. Dempsey^d, Thomas J. Enke^d, John Le^d, Hunter J. Winstead^d, José R. Boquín^d, and Robert R. Kane^{a,b,c}

^aDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, TX 76798, USA

^bInstitute of Biomedical Studies, Baylor University, One Bear Place #97224, Waco, TX 76798, USA

^cBaylor Institute for Immunology Research, Baylor Research Institute, 3434 Live Oak Street, Dallas, TX 75204, USA

^dDepartment of Chemistry, Augustana College, 639 38th Street, Rock Island, IL 61201, USA

Abstract

Protein conjugates of toll-like receptor 7 agonists have been shown to elicit powerful immune responses. In order to facilitate our studies in this area our group has developed efficient syntheses for a number of functionalized derivatives that retain immune stimulatory activity.

Keywords

Toll-like receptor; Adenine derivatives; Vaccines; Immune activation

Pathogens are initially detected by the innate immune system upon the binding of their associated ‘signature’ molecules to germline-encoded pathogen-associated molecular pattern (PAMP) receptors.¹ Toll-like receptor 7 (TLR7) is an endosomal member of the Toll-like receptor family of PAMP recognition proteins.² Virus-associated single stranded RNA is the molecular pattern that activates TLR7, thereby initiating an antiviral immune response involving the maturation of dendritic cells (DC), the secretion of cytokines, and the up-regulation of major histocompatibility complex.^{3,4} The development of immunotherapeutic compounds that act via the activation of PAMP receptors, including TLR7, is an active area of research.

© 2014 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1-254-710-4556; fax: +1-254-710-4272; Bob_Kane@baylor.edu.

Supplementary Material

Complete experimental and analytical data for all new compounds.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Potent small molecule TLR7 agonists have been discovered, including imidazoquinolines such as compound **1**⁵ and substituted adenine derivatives such as compound **2**^{6–8} (Figure 1). Unfortunately, the clinical utilization of these compounds is significantly limited by side-effects resulting from the overwhelming generation of cytokines subsequent to systemic administration. Accordingly, the clinical application of compound **1** has been limited to localized administration such as formulation for topical use for the treatment of skin diseases.⁹ A wide variety of derivatives of these compounds have been synthesized in hopes of identifying analogues that elicit especially potent or selective immune responses^{10–15} or to provide compounds with improved solubility,¹⁶ bioavailability,¹⁷ or kinetic properties.^{18,19}

Previous work has demonstrated that TLR7 ligands can be conjugated to a variety of molecules (lipids, peptides, and proteins) while retaining their potent agonist activity *in vitro* and *in vivo*.^{20–23} Specifically, para substituents on compounds such as **2** are well tolerated, as demonstrated by the conjugation of aldehyde **3** to a to proteins and peptides with retention of TLR7 stimulation.²² Our group is interested in synthesizing anti-DC receptor antibody/TLR7 agonist conjugates in order to facilitate the targeted delivery of these immunostimulatory compounds, thereby potentially avoiding the problems associated with systemic administration. This paper reports the efficient synthesis of functionalized TLR7 agonists **4** that can potentially serve as the starting point for the synthesis of antibody conjugates.

The synthesis of the known^{6–8} non-functionalized TLR agonist **4a** was initially explored. Benzylation of commercially available chloroadenine **5** (which can also be conveniently synthesized on a large scale by amination of 2,6-dichloropurine¹⁸) proceeded smoothly, affording the desired product in good yield by simple precipitation (Scheme 1). This route avoids the formation of isomers (requiring chromatographic separation) observed upon benzylation of 2,6-dichloropurine. Introduction of the alkoxy substituent (again, with a simple isolation by precipitation) followed by bromination provides **6a** in good yield. In our hands the bromination proceeded very slowly in CH₂Cl₂ or CHCl₃ requiring a very large excess of bromine and multiple Na₂S₂O₃ washes to isolate the pure product. However, in acetic acid with sodium acetate the bromination proceeds very efficiently to afford pure product that can be isolated by filtration from the reaction mixture. Finally, while **6a** could be hydrolyzed using a two-step procedure (methanolysis followed by acidic cleavage of the methyl ether), we found that simple treatment with a solution of NaOH in water/methanol solvent gave direct access to the desired product in one step (Scheme 2). Overall, our optimized procedure was scalable and afforded the desired TLR7 agonist **4a** in four steps with 70% overall yield without chromatographic purification.

A similar reaction sequence also readily afforded iodide **4b** (55% for 4 steps). However when preparing **4c** we observed that yields were adversely impacted by the concomitant formation of nitrile hydrolysis/alcoholysis side-products during the reactions with sodium butoxide and methanolic sodium hydroxide. Nitrile **4c** was therefore most reproducibly isolated via a two-step methanolysis/hydrolysis protocol (which also provided amide **4e**; Scheme 3). In order to avoid the formation of similar mixtures during the preparation of **4d**, water was added directly to the sodium butoxide reaction mixture after chloride

displacement was complete. Refluxing the butoxide/water mixture completed the nitrile hydrolysis to afford, after bromination under standard conditions, carboxylic acid **6d** in good yield. Hydrolysis of **6d** then afforded the useful TLR7 agonist **4d**.

Iodide **7**, which was prepared in good yield by the reaction of **6b** with methoxide, was prepared in order to investigate functionalization using Sonogashira conditions.²⁴ We were pleased to find that **7** reacted cleanly with functionalized alkynes (followed by deprotection of BOC-protected amines) to provide arenes **4f**, **4g**, and **4h** (Scheme 4). Notably, compounds **4g** and **4h** contain primary amines that can be used to conjugate to proteins or other compounds.

Finally, carboxylic acid **4d** has been linked, using COMU as a coupling agent, to two different mono-BOC-protected diamines which were cleanly deprotected using TFA to afford two additional amino-substituted TLR7 agonists **4i** and **4j** (Scheme 5).

Preliminary biological evaluations (TLR7 reporter cell line assays and cytokine release from peripheral blood mononuclear cells) have demonstrated that each of these new compounds (**4b–j**) are active TLR7 agonists (data not shown). Several of these new compounds are well functionalized for protein conjugation, and we are presently attaching them to targeting proteins and characterizing their biological properties.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by funding from Baylor University (URC), the Baylor Health Care System Foundation, and the NIH (U19 AI057234).

References

1. Medzhitov R, Janeway CA Jr. Cell. 1997; 91:295–298. [PubMed: 9363937]
2. Takeda K, Akira S. Int Immunol. 2005; 17:1–14. [PubMed: 15585605]
3. Aderem A, Ulevitch RJ. Nature. 2000; 406:782–787. [PubMed: 10963608]
4. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Eur J Immunol. 2001; 31:3388. [PubMed: 11745357]
5. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Nat Immunol. 2002; 3:196–200. [PubMed: 11812998]
6. Naito T, Nakagawa S, Okita TA, Yamashita H, Yamasaki T, Kamei H, Tomatsu K, Imanishi H, Kawaguchi H. Chem Pharm Bull. 1982; 30(6):2011–2019. [PubMed: 7127596]
7. Hirota K, Kazaoka K, Niimoto I, Kumihara H, Sajiki H, Isobe Y, Takaku H, Tobe M, Ogita H, Ogino T, Ichii S, Kurimoto A, Kawakami H. J Med Chem. 2002; 45:5419–5422. [PubMed: 12459008]
8. Hirota K, Kazaoka K, Niimoto I, Sajiki H. Org Biomol Chem. 2003; 1(8):1354–1365. [PubMed: 12929666]
9. Chang YC, Madkan V, Cook-Norris R, Sra K, Tying S. South Med J. 2005; 98:914–920. [PubMed: 16217984]
10. Shukla NM, Mutz CA, Malladi SS, Warshakoon HJ, Balakrishna R, David SA. J Med Chem. 2012; 55:1106–1116. [PubMed: 22239408]

11. Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS, David SA. PLoS ONE. 2012; 7(8):e43612. [PubMed: 22952720]
12. Weterings JJ, Khan S, van der Heden GJ, Melief CJM, Overkleeft HS, van der Burg SH, Ossendorp F, van der Marel GA, Filippov DV. Bioorg Med Chem Lett. 2009; 19:2249–2251. [PubMed: 19299126]
13. Christopherson MS, Broom AD. Nucleic Acids Res. 1991; 19:5719–5724. [PubMed: 1945849]
14. Hirota K, Kazaoka K, Sajiki H. Bioorg Med Chem. 2003; 11:2715–2722. [PubMed: 12788345]
15. Jin G, Wu CCN, Tawatao RI, Chan M, Carson DA, Cottam HB. Bioorg Med Chem Lett. 2006; 16:4559–4563. [PubMed: 16784848]
16. Nakamura T, Wada H, Kurebayashi H, McNally T, Bonnert R, Isobe Y. Bioorg Med Chem Lett. 2013; 23:669–672. [PubMed: 23265901]
17. Kurimoto A, Ogino T, Ichii S, Isobe Y, Tobe M, Ogita H, Takaku H, Sajiki H, Hirota K, Kawakami H. Bioorg Med Chem Lett. 2004; 12:1091–1099.
18. Kurimoto A, Ogino T, Ichii S, Isobe Y, Tobe M, Ogita H, Takaku H, Sajiki H, Hirota K, Kawakami H. Bioorg Med Chem. 2003; 11:5501–5508. [PubMed: 14642594]
19. Kurimoto A, Hashimoto K, Nakamura T, Norimura K, Ogita H, Takaku H, Bonnert R, McNally T, Wada H, Isobe Y. J Med Chem. 2010; 53:2964–2972. [PubMed: 20232824]
20. Weterings JJ, Khan S, van der Heden GJ, Drijfhout JW, Melief CJM, Overkleeft HS, van der Burg SH, Ossendorp F, van der Marel GA, Filippov DV. Bioorg Med Chem Lett. 2006; 16:3258–3261. [PubMed: 16581248]
21. Shukla NM, Lewis TC, Day TP, Mutz CA, Ukani R, Hamilton CD, Balakrishna R, David SA. Bioorg Med Chem Lett. 2011; 21:3232–3236. [PubMed: 21549593]
22. Wu CCN, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, Carson DA. Proc Nat Acad Sci USA. 2007; 104(10):3990–3995. [PubMed: 17360465]
23. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CCN, Corr M, Wrasidlo W, Cottam HB, Carson DA. Bioconjugate Chem. 2009; 20:1194–1200.
24. Chinchilla R, Carmen Najera C. Chem Rev. 2007; 107:874–922. [PubMed: 17305399]

Figure 1.
Synthetic TLR-7 agonists

Scheme 1.

Reagents and conditions: i. ArCH₂Br, K₂CO₃, DMSO, rt, ii. *n*-BuONa/*n*-BuOH, reflux, iii. *n*-BuONa/*n*-BuOH, reflux, then add H₂O, reflux, iv. Br₂, CH₂Cl₂, rt 12 h *or* Br₂, AcOH, AcONa, rt, 1 h.

Scheme 2. Reagents and conditions: NaOH, CH₃OH, reflux.

Scheme 3.

Reagents and conditions: i. CH₃ONa, CH₃OH, reflux, 61%, ii. HCl (conc), 43%, iii. HCl (conc), 15%.

Scheme 4.

Reagents and conditions: i. CH_3ONa , CH_3OH , reflux, 86%, ii. $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$, CuI , Et_3N , then propargyl alcohol, reflux, iii. NaI , TMSCl , CH_3CN , reflux, iv. $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$, CuI , Et_3N , then BOC-propargyl amine, reflux, v. Pd/C , H_2 , MeOH , rt

Scheme 5.

Reagents and conditions: i. BOC-ethylenediamine, DIPEA, COMU, DMSO, DCM, 0°-rt, 2 h, ii. TFA, DCM, rt, 1 h, iii. BOC-NH-CH₂CH₂OCH₂CH₂OCH₂CH₂-NH₂, DIPEA, COMU, DMSO, DCM, 0°-rt, 2 h.